Risks and benefits of reducing the number of drugs to treat HIV-1 infection-Reference-Cited by-同舟云学术

Risks and benefits of reducing the number of drugs to treat HIV-1 infection

Published:2021-02-24 Issue:4 Volume:20 Page:397-409
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Cadiñanos Julen¹,Montejano Rocio¹,de Miguel Buckley Rosa¹,Marcelo Cristina²,Arribas Jose R.³

Affiliation:

1. HIV Unit, Internal Medicine Service, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain

2. Internal Medicine Service, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain

3. Infectious Diseases Unit, Despacho 3.3. Hospital La Paz. IdiPAZ, Madrid, Spain

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2021.1887135

Reference95 articles.

1. European AIDS clinical society guidelines[Internet]. [cited 2020 Oct 12]. Available from: https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html.

2. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

3. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – a Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV [Internet]. [cited 2020 Oct 12]. Available from: https://clinicalinfo.hiv.gov/es/guidelines.

4. A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

5. Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial;The Lancet HIV;2024-06

2. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial;The Lancet HIV;2024-06

3. Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT);eClinicalMedicine;2024-03

4. HBcAb Positivity as a Risk Factor for Missing HIV RNA Undetectability after the 3TC+DTG Switch;Viruses;2024-02-23

5. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir‐based dual combinations;HIV Medicine;2024-01-23